Seres Therapeutics Inc (MCRB) Stock Price and Analyst Predictions

The stock has a 36-month beta value of 2.66. Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 0 as “overweight,” 2 as “hold,” and 0 as “sell.”

The public float for MCRB is 6.44M, and at present, short sellers hold a 10.55% of that float. On July 01, 2025, the average trading volume of MCRB was 101.85K shares.

MCRB) stock’s latest price update

The stock of Seres Therapeutics Inc (NASDAQ: MCRB) has increased by 22.09 when compared to last closing price of 9.1. Despite this, the company has experienced a 49.73% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-27 that Results highlight potential role of SER-155 in promoting peripheral T-cell recovery and immune reconstitution to support favorable outcomes post allogeneic hematopoietic stem cell transplant (allo-HSCT) Results highlight potential role of SER-155 in promoting peripheral T-cell recovery and immune reconstitution to support favorable outcomes post allogeneic hematopoietic stem cell transplant (allo-HSCT)

MCRB’s Market Performance

MCRB’s stock has risen by 49.73% in the past week, with a monthly rise of 56.70% and a quarterly drop of -22.95%. The volatility ratio for the week is 15.69% while the volatility levels for the last 30 days are 8.80% for Seres Therapeutics Inc The simple moving average for the past 20 days is 37.53% for MCRB’s stock, with a -20.92% simple moving average for the past 200 days.

Analysts’ Opinion of MCRB

Many brokerage firms have already submitted their reports for MCRB stocks, with Chardan Capital Markets repeating the rating for MCRB by listing it as a “Neutral.” The predicted price for MCRB in the upcoming period, according to Chardan Capital Markets is $6 based on the research report published on May 08, 2025 of the current year 2025.

Oppenheimer gave a rating of “Outperform” to MCRB, setting the target price at $12 in the report published on June 26th of the previous year.

MCRB Trading at 37.00% from the 50-Day Moving Average

After a stumble in the market that brought MCRB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.69% of loss for the given period.

Insider Trading

Reports are indicating that there were more than several insider trading activities at MCRB starting from Young Teresa L., who sale 63 shares at the price of $7.28 back on May 16 ’25. After this action, Young Teresa L. now owns 5,044 shares of Seres Therapeutics Inc, valued at $459 using the latest closing price.

Shaff Eric D., the CEO and President of Seres Therapeutics Inc, sale 220 shares at $7.28 during a trade that took place back on May 16 ’25, which means that Shaff Eric D. is holding 10,102 shares at $1,602 based on the most recent closing price.

Stock Fundamentals for MCRB

The total capital return value is set at -0.88. Equity return is now at value -3758.21, with -26.46 for asset returns.

Based on Seres Therapeutics Inc (MCRB), the company’s capital structure generated 0.64 points at debt to capital in total, while cash flow to debt ratio is standing at -0.97. The debt to equity ratio resting at 1.77. The interest coverage ratio of the stock is -33.82.

Currently, EBITDA for the company is -121.31 million with net debt to EBITDA at -0.26. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.11.

Conclusion

To sum up, Seres Therapeutics Inc (MCRB) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.

Related Posts

favicon-nh
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.